| Sep 5 |
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
|
| Sep 4 |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 1 |
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
|
| Sep 1 |
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
|
| Aug 29 |
Cytokinetics to Participate in September Investor Conferences
|
| Aug 13 |
Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities
|
| Aug 13 |
Cytokinetics cut at Goldman Sachs on diminished strategic interest
|
| Aug 10 |
Cytokinetics, Incorporated (CYTK) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
|
| Aug 8 |
Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
|
